Remote Sensing for ADRD-Specific Activities Identification in Older Adults
University of Missouri-Columbia · NCT07120347
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 16
- US sites recruiting
- 1
- Study start
- August 1, 2024
- Record last updated
- August 13, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The investigators aim to use smart-home sensors and artificial intelligence (AI) to monitor and detect Alzheimer's Disease and Related Dementias (ADRD)-specific daily activities among older adults, with the goal of early symptom detection and personalized support. Dementia, which impacts memory and cognition, remains a global concern. In the United States, more than 6.7 million individuals aged 65 and older are living with ADRD, and projected annual healthcare costs are expected to reach $1 trillion by 2050. This underscores the need for deeper understanding and innovative support. To address the unique challenges associated with ADRD, such as cognitive decline, personalized strategies that promote independent well-being are essential. Smart-home sensors can support older adults with ADRD as they continue to live in their homes. These sensors provide real-time data on health and daily activities, offering insights into their daily lives. However, adoption of these technologies is low, and the practical application of AI remains limited. This highlights the need for further research to make these devices more accessible to this population. The investigators' aims include:
Conducting focus groups with individuals with and without ADRD and their caregivers to identify daily activities that can be measured using in-home sensors; Collecting in-home sensor data from older adults with and without ADRD; and Using AI to develop a tool for recognizing daily activities. The integration of smart-home sensors with advanced data-analysis techniques holds significant potential for transforming the support and care provided to individuals with ADRD. Ultimately, the investigators' findings will contribute to improving the quality of life for affected individuals and alleviating the burden on caregivers and healthcare systems.
Being studied: Remote Ambient Sensor System
Conditions: Alzheimer Disease and Related Dementias (ADRD); Mild Cognitive Impairment (MCI)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Community-dwelling, English-speaking adults aged ≥ 50 years
- Clinical diagnosis of mild cognitive impairment or mild dementia (ADRD)
- Diagnosis established by a neuropsychologist, neurologist, or geriatrician within the University of Missouri Healthcare System
- Diagnosis confirmed using the latest consensus criteria and verified through record review
- No restriction on the etiology of the cognitive disorder (e.g., Alzheimer's disease, vascular dementia, mixed dementia)
Exclusion Criteria
- Clinical Dementia Rating (CDR) global score > 1 (moderate or severe dementia)
- Cognitive or functional impairments that would preclude meaningful participation in daily activities
Recruiting US locations
University of Missouri
Columbia, MO 65211
Site contact: Knoo Lee, PhD · 5738840421 · knoolee@missouri.edu
Study contacts (from the official record)
- Knoo Lee, PhD · 5738840421 · knoolee@missouri.edu
Similar studies in Missouri
All neurology studies in Missouri →- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
University of Pennsylvania
- Location
- St Louis, MO + 2 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- St Louis, MO + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Chesterfield, MO + 24 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- St Louis, MO + 21 other US sites
- Eligibility basics
- Ages 18–75